2028, Pharmacokinetics and Virus - Drug Discovery Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2028

Pharmacokinetics

Virus

Improving quality control for CAR T cell therapies

Drug Discovery World

AUGUST 10, 2022

CAR T cells are made by transfecting T cells with a transgene that encodes the CAR protein using either a virus, a transposon system, or mRNA. MOI is the ratio between virus concentration and cell concentration, and with ddPCR assays, the researchers found that as MOI increased, so did copy number.

Therapies

Therapies Virus Treatment Engineering

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. An update on Pfizer’s potential first-in-class maternal vaccine candidate for the prevention of respiratory syncytial virus (RSVpreF). BNT162 mRNA-based Vaccine Program. for RSV A and 18.0

Vaccine

Vaccine Therapies Trials Clinical Trials

Improving quality control for CAR T cell therapies

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

Stay Connected